期刊文献+

辛伐他汀调脂治疗冠心病的疗效观察 被引量:2

The efficacy and safety of simvastatin in treatment of patients with coronary heart disease
下载PDF
导出
摘要 目的观察不同剂量辛伐他汀治疗冠心病伴高血脂症的疗效及不良反应。方法将100例冠心病伴高血脂症患者随机分为3组,A组给予辛伐他汀10mg/d口服,B组给予辛伐他汀20mg/d口服,C组给予辛伐他汀40mg/d口服。3组分别在治疗前及治疗过程中定期检测血清胆固醇(TC)、低密度脂蛋白(LDL—C)等及安全性指标(ALT、Cr、BUN及CK),比较不同剂量辛伐他汀的疗效及安全性。结果辛伐他汀常规剂量降低TC、LDL—C的作用显著,且不良反应较少。结论辛伐他汀常规剂量治疗冠心病伴高血脂症可取得较满意疗效。 Objective To evaluate the efficacy and safety of different doses of simvastatin in treatment of patients with coronary heart disease (CHD).Methods 100 patients with definite diagnosis of CHD were enrolled and divided into three groups treated with 10 mg (n=40),20mg (n=40) and 40mg(n=20) simvastatin, once each night, respectively. The fasting serum levels of total cholesterol (TC),low-density lipoprotein cholesterol (LDL-C),as well as functions of liver and kidney were determined before medication, 12th and 24th week after initial medication ,respectively. Results The levels of TC and LDL-C levels in 20 mg group were continuously lower and the adverse effects including abnormal liver enzyme in 20mg group was fewer. Conclusion The simvastatin 20 mg in treatment of CHD is safe and more effective in lowering cholesterol ,causing more CHD cases to reach the target level of cholesterol.
作者 李蓉 邹立新
出处 《国际医药卫生导报》 2008年第22期59-61,共3页 International Medicine and Health Guidance News
关键词 辛伐他汀 冠心病 高血脂症 Coronary heart disease Simvastatin Hyperlipidemia
  • 相关文献

参考文献8

  • 1Assmann G, Carmena R, Cullen P, et al. Coronary heart disease:Reducing the risk:A worldwide view. International task force for the prevention of coronary heart disease[J].Circulation, 1999,100(18):1930-1938
  • 2De-Feyter PJ. Lipids and coronary restenosis:An elusive link[J].Eur heart J, 1999, 20 (19) : 1371-1374
  • 3Scandinavian Simavastadin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastadin Survival Study(4S)[J].Lancet, 1994,344: 1383-1389
  • 4Yilmaz M ,Bukan N ,Ayvaz G, et al. The effects of rosiglitazone and metform in onoxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome[J].Hum Reprod, 2005,20(12): 3333-3340
  • 5方圻,王钟林,宁田海,邵耕,陈在嘉,陆宗良,李健斋,林传骧,周北凡,诸骏仁,诸永康,陶萍,陶寿淇,龚兰生,顾复生,游凯,戴玉华.血脂异常防治建议[J].中华心血管病杂志,1997,25(3):169-175. 被引量:3067
  • 6顼志敏,赵文淑,王桂芝,李静,金新新,高明明,杨新春,胡大一.不同剂量辛伐他汀调脂治疗冠心病的疗效及安全性研究[J].中华老年心脑血管病杂志,2001,3(4):227-229. 被引量:11
  • 7张大庆.不同剂量普伐他汀治疗冠心病伴高血脂症疗效观察[J].现代中西医结合杂志,2008,17(7):992-993. 被引量:2
  • 8Grundy sm, Clecman JI, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines[J]. Circulation, 2004,110:227-239

二级参考文献12

  • 1Terje R, Pedersen TR. Lars Wilhelmsen, et al. Scandinavian Simvastatin Survival Study Group. Randomized trial of chplesterol lowering in 4 444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study(4S) [J]. Lancet, 1994,344:1383-1389
  • 2The long-term intervention with pravastatin in ischaemic chsease (LIPID)study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels[J] .N Engl J Ned. 1998,339:1349-1357.
  • 3Deskur-Smielecka E, Wykr Towicz A. The influence of short-term treatment with simvastatin on the inflammatory profile of patients with hyper-cholesterolemia[J] .Coronn Artery Dis,2001,12:143-148.
  • 4Santos AF, Kifel E. Safety and efficacy' of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebocontrolled stutly [J] .Transplant Proc, 200 L,B3 : 1194-1195.
  • 5Pedersen TR. Pro and con: low-density lipoprotein cholesterol lowing is and will be the key to the future of lipid management[J].Am J Cardiol,2001,8:27(5A) :8B-12B.
  • 6Shepherd J, Prevention of coronary heat disease with pravastatin in men with hypercholesterolemia [ J ]. N Engl J Med, 1995, 333: 1301
  • 7Heart Protection Study Collaborative Group MRC. BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals a randomized placebo-controlled trial [J ]. Lancet, 2002,360 : 7 - 22
  • 8Yilmaz M, Bukan N,Ayvaz G, et al. The effects of rosiglitazone and metform in onoxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome[J]. Hum Reprod, 2005, 20(12) :3333 - 3340
  • 9Haffner SM. Dyslipidemia management in adults with diabetes[J]. Diabetes Care,2004,27(Suppl 1) :S68 - 71
  • 10方圻,王钟林,宁田海,邵耕,陈在嘉,陆宗良,李健斋,林传骧,周北凡,诸骏仁,诸永康,陶萍,陶寿淇,龚兰生,顾复生,游凯,戴玉华.血脂异常防治建议[J].中华心血管病杂志,1997,25(3):169-175. 被引量:3067

共引文献3072

同被引文献7

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部